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Abstract 
Background: Treatment of latent tuberculosis infection (LTBI) is an important component of 
tuberculosis (TB) control and this study updates our previous (network) meta-analysis on the 
best LTBI treatment options to inform public health action and the programmatic 
management of LTBI. 
Purpose: To evaluate the comparative efficacy and harms of LTBI treatment regimens aimed 
at preventing active TB among adults and children. 
Data sources: PubMed, Embase, Web of Science to 8th of May 2017; clinical trial registries; 
conference abstracts, including previous searches to 29th January 2014 and new searches 
since.  No language restrictions. 
Study selection: Randomized controlled trials that evaluated human LTBI treatment and 
recorded at least one of two pre-specified endpoints (preventing active TB, hepatotoxicity).  
Data extraction: Data from eligible studies were independently extracted and study quality 
assessed by two investigators, according to a standard protocol. 
Data synthesis: The network meta-analysis of new and previously included studies showed 
that isoniazid regimens of six or 12-72 months (odds ratio [OR] 0.31 [95% credible interval; 
CrI] 0.21- 0.47) , rifampicin only regimens OR 0.25 (CrI 0.11-0.57) , rifampicin-isoniazid 
regimens of three to four months OR 0.57 (CrI 0.31-1.02) , rifampicin-isoniazid-
pyrazinamide OR 0.21 (CrI 0.11-0.41), and rifampicin-pyrazinamide OR 0.33 (CrI 0.18-0.58) 
regimens were efficacious compared with no treatment. There was evidence for efficacy of 
weekly rifapentine-isoniazid regimens OR 0.36 (CrI 0.18-0.73). There was no conclusive 
evidence that HIV status altered treatment efficacy. 
Limitations: Sparse evidence for many comparisons and for hepatotoxicity outcomes was 
available and high or unknown risk of bias for many studies. 
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Conclusions: We found evidence for the efficacy and safety of six month isoniazid 
monotherapy and for rifampicin monotherapy as well as combination therapies with three to 
four months of isoniazid and rifampicin..  
Registration: CRD42016037871 (PROSPERO). 
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Background 
Tuberculosis (TB) is a global priority infectious disease with an estimated 1.4 million deaths 
in 2015 (1). A number of strategies are required if the Sustainable Development Goal of 
ending the global TB epidemic by 2030 is to be reached (2); tackling latent TB infection 
(LTBI) including providing preventive treatment to persons at high risk of TB, is a key action 
to achieve both the Sustainable Development Goals and the targets of the World Health 
Organization’s  End TB strategy(3).  
 
A number of different treatment regimens for LTBI are currently available globally; five are 
recommended by the World Health Organization (4) and four of these by the Centers for 
Disease Control and Prevention (United States)(5). Evidence on efficacy of shorter regimens 
with a reduced pill burden is evolving, but more information on effectiveness is still urgently 
needed(6).   
 
We previously published a network meta-analysis review of randomized controlled trials 
(RCTs) that identified the most effective and least harmful preventive treatment regimens (7). 
The results of this meta-analysis and Bayesian network analysis served as the evidence base 
for the 2014 World Health Organization’s LTBI guidelines (4,8). As part of the European 
Centre for Disease Prevention and Control (ECDC)’s decision to provide new guidance on 
programmatic LTBI control in the European Union (EU)/ European Economic Area (EEA) 
and candidate countries, a need to update our 2014 review was identified (9) - the results of 
which are presented in this manuscript.  
 
Methods 
To ensure consistency, we used the same methodology as in our previous study (7). We 
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summarise this approach briefly below. We registered this study in the PROSPERO database 
(CRD42016037871).  
 
Data sources and searches 
PubMed, EMBASE, Web of Science and grey literature were searched until 8 May 2017. We 
reviewed and included our previous search and added all relevant articles, focussing on the 
time after the previous search (Annex 1).  
 
Study selection and extraction 
We followed the same selection criteria as before and included RCTs that analysed LTBI 
treatments, with no language restrictions. Exclusion criteria were non-randomised or 
observational studies, animal studies, or those, which did not have sufficient information on 
at least one of our two main end points (hepatotoxicity or development of active TB). As in 
our previous study, two of five potential reviewers (DZ, NB, HRS, MCL, MvdW) 
independently performed title, abstract, and full text screening, and resolved discrepancies 
through consensus or, if needed, through consultation with a third reviewer.  
 
Data extraction and quality assessment 
Two reviewers (DZ, NB) independently performed data extraction to a standardised template, 
which included details about the study, population and follow up, treatment regimens, and 
data on outcomes of interest. Study quality was assessed by the same two reviewers using the 
quality assessment tool from Higgins et al. (10). Disagreements were resolved in consultation 
with a third reviewer (MvdW). 
 
Data synthesis and analysis 
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We compared both of the main outcomes – TB events and hepatotoxicity - using both 
conventional random effects meta-analysis and a network meta-analysis (NMA) approach. 
Analyses included grouping and stratification of treatment regimens and estimating 
differences in  treatment effects between groups, via ratios of odds ratios (ROR), according to 
study-level variables as described in Stagg et al. (Data Supplement 1) (7). Pre-defined 
stratified analyses required studies to be grouped by (a) HIV status (HIV positive population 
versus not HIV positive population including low proportion HIV positive [≤5%, including 
no individuals HIV positive] and not stated), (b) age (adults vs. children (<18)), (c) 
immunosuppressed (as a result of HIV infection and other conditions) versus not, (d) TB 
incidence in the country of study at the time of the RCT (high versus low incidence). The 
robustness of the HIV stratification was also tested by sensitivity analysis using a stricter 
definition of non-HIV status (non-HIV group only including studies where being HIV 
positive was an exclusion criterion and pre-1990 publications when endemic levels were low) 
(11). 
 
Analyses of study and review quality were also undertaken as previously. The effect of study 
quality domains such as inadequate/unclear blinding, allocation concealment and 
randomisation, incomplete outcome assessment etc. were also assessed by estimating RORs 
between studies with adequate vs. inadequate/unclear study domains to determine whether 
these were associated with a change in estimated treatment efficacy. Publication bias was 
assessed in a similar way, to determine whether average standard errors (SE) of log odds 
ratios for each study were associated with a difference in estimated treatment efficacy. 
Network consistency was examined by informally comparing estimated treatment effects 
from NMA with standard pair-wise meta-analysis and comparing deviance information 
criteria (DIC) statistics for the NMA with an inconsistency model, in which the difference 
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between each possible comparison is unconstrained, rather than the usual NMA assumption 
of consistent treatment effects for different comparisons. 
We used STATA 13 (Statacorp, Texas) for data processing and classical analysis, with the 
Bayesian NMA conducted using WinBUGS 1.4.3 (Medical Research Council, UK). Most 
figures were also produced with STATA, except flow charts for which Microsoft PowerPoint 
for Mac (Microsoft Corp) was used.  
 
Role of Funding Source 
Funding sources are outlined above. None of the funding sources had any influence or role in 
this review. 
 
Results 
In the update of the review, 1576 articles were identified in the databases search and of these, 
1434 were left after de-duplication (Data Supplement 2). Eight additional papers were 
selected that were either used to update or to add to the 53 studies included in the original 
review (Data Supplement 3). Two of the added papers provided data from studies that had 
been included in the original review (12,13). Samandari (2015) (12) overlapped with 
Samandari (2011) (14); the former was used to provide an update for the outcome of 
development to active TB, but did not report any additional hepatotoxicity results. Sterling 
(2016) (13) provided an update solely for the people living with HIV included in their 
original 2011 paper (15). In the interest of analytical power we thus retained Sterling (2011) 
for the overall analysis, but utilised Sterling (2016) (13) when performing the HIV stratified 
analysis. In Danel (16), there were four arms, two comparing patients with deferred 
antiretroviral therapy (ART) and two comparing patients with early ART initiation. Data 
were extracted and analysed separately for both groups of patients. 
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Four of the new papers contained extractable data on hepatotoxicity (12,16–18) and all eight 
on development of active TB (12,13,16–21). Six of the eight papers were conducted in TB 
high incidence countries (12,16,17,19–21) and six were solely in people living with HIV 
(12,13,16–19). All new studies included isoniazid (INH) monotherapy in at least one arm; 
additionally, one included INH-rifapentine (RPT)(13), one included INH-ethambutol 
(EMB)(21) and one included both INH-rifampicin (RMP) and INH-pyrazinamide (PZA)(18) 
(Data Supplement 4). Sixteen regimens were thus included in the evidence network, one 
more (INH-EMB 12 months) than in the previous review (Table 1, Figure 1 and 2) 
 
Study quality 
A number of the newly included papers had a high or unknown risk of bias (Data Supplement 
7). As previously, however, all study quality indicators for high risk of bias were only 
associated with very weak evidence for modification of treatment efficacy; for instance 
inadequate/unclear allocation concealment had a ratio of odds ratios (ROR) of 0.74 (95% 
credible interval [CrI] 0.31-1.42). Similar results were observed for high or unclear risk of 
bias due to inadequate randomisation and blinding, which is consistent with other studies 
(22). The ROR for incomplete/unclear outcome reporting versus adequate was 0.91 (95% CrI 
0.42-1.43) and for selective reporting 1.03 (95% CrI 0.55-1.75). 
Results for hepatotoxicity were highly uncertain for all domains due to the sparsity of data 
and there was no firm evidence with which to confirm or reject any modification of treatment 
effects according to study quality domains. 
 
Prevention of active TB 
An assessment of sixteen different regimens found that INH regimens of six or 12-72 months, 
RMP only regimens, RMP-INH regimens of three to four months, RMP-INH-PZA, RMP-
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PZA, and INH-EMB 12 month regimens were efficacious, with p-values <0.05.Table 1 
shows estimated odds ratios (ORs) for each regimen vs. placebo and no treatment under the 
NMA model. The INH-EMB 12 month regimen showed the greatest effect, but with 
substantial uncertainty (OR=0.20, 95% CrI: 0.04, 0.82) and INH-EMB for shorter durations 
showed no evidence of efficacy. Two RFB-INH regimens, which used different doses of 
RFB, both showed ORs of 0.30 but with substantial uncertainty. The RMP-INH-PZA 
combination regimen showed a two-thirds reduction in TB and was strongly significant 
(OR=0.35, 95% CrI: 0.19, 0.61). Additionally, the use of (three or four months of) RMP and 
three or four months of RMP-INH appeared to be efficacious, with reductions in active TB of 
a half or more, although these results are based on limited data. The ORs for all lengths of 
INH had overlapping CrIs and varying levels of uncertainty, with INH regimens of 6 or 12 
months or more having the most robust evidence and the with greatest efficacy for 12 months 
or more. Treatment rankings, while not providing quantified differences of treatment 
efficacy, are also useful in understanding uncertainty in the evidence base. For instance, the 
INH-EMB 12 month regimen had the highest median rank, but credible intervals also 
included it being ranked among the poorest (95% Cri 1st-11th); the INH regimen of 12 
months or more had more certainty but was ruled out of being one of the best, and a number 
of other regimens had 95% CrIs that included being the best-ranking treatment (RFB-INH 
regimens, RMP and RMP-INH-PZA). Treatment rankings are shown in Table 1 and 
histograms of rankings are available in Data Supplement 8 and 9. 
 
Stratifying the results on the basis of HIV status showed no significant differences in effect 
estimates for each regimen or the overall pattern of results when comparing studies in 
exclusively HIV positive populations (24 studies) versus those without HIV or where this 
was not stated (28 studies; Data Supplement 9). The estimated ROR for the overall difference 
10 
 
in treatment efficacy (1.45, 95% CrI 0.89-2.31) indicates an inconclusive but potentially 
weaker efficacy for treatment versus placebo/no treatment in HIV positive individuals. The 
standard deviation of the random effect for treatment modification was 0.164 (95% CrI 
0.007-0.957), indicating reasonable consistency across regimens for differences in treatment 
efficacy, albeit with wide CrIs. 
 
Inclusion of high versus low TB incidence in the country of study as a covariate reduced 
between-study variability; treatment was generally less efficacious in high incidence 
populations (ROR 1.58, 95% CrI 1.01-2.48). Subgroup analysis by year and age also resulted 
in little change in treatment rankings. Using covariate models, treatment effects were 
attenuated slightly in more recent years, although the evidence for this was fairly weak (ROR 
1.58, 95% CrI 0.82-2.82 and 1.34, 95% Cr: 0.59-2.38 for 1992-2004 and 2005 onwards 
versus pre-1992, respectively). There was no evidence of a relationship between adherence 
and efficacy (ROR 0.94 per 10% decrease, 95% CrI 0.54-1.30). Restricting analysis to culture 
confirmed TB cases only did not alter our conclusions. 
 
Comparing the results derived from a random effects pairwise meta-analysis with the 
corresponding estimate from the NMA model revealed some differences in OR estimates 
between the models (Figure 2, Data Supplement 5 and 10). Many treatment comparisons 
showed a stronger beneficial effect in a standard pairwise meta-analysis compared to results 
from NMA; however the differences had p-values greater than 0.05 and were predominantly 
where the effect estimates from pairwise meta-analysis were imprecise. 
 
Hepatotoxicity 
Due to the limited data on hepatotoxicity, results from the direct comparison are presented 
11 
 
here. Hepatotoxicity results from the NMA are shown in Table 2. Estimates were largely 
consistent with the direct comparisons (Data Supplement 7, 9 and 11). Twenty different pair-
wise comparisons were available. Results from the standard meta-analysis suggest that RMP 
only and RPT-INH regimens had lower rates of hepatotoxicity than an INH only regimen of 
six, nine, or 12-72 months (Data Supplement 6 and 10). RMP-INH regimens also had lower 
hepatotoxicity versus INH only regimen, although there was only good evidence for this 
when compared to INH regimens of 12-72 months. There was good evidence that regimens 
containing PZA had higher hepatotoxicity compared to six months of INH or 12 weeks of 
RPT-INH. No data were available regarding the hepatotoxicity of the RFB-INH and INH-
EMB regimens. Stratifying the results on the basis of immunosuppression, HIV status and TB 
incidence did not markedly impact on our conclusions. 
 
Inconsistency 
Comparing inconsistency models with the consistency models revealed no evidence that the 
additional complexity of the former was required (Data Supplement 12). However, as this 
study used a full random effects model and the data exhibited a moderate level of between-
study heterogeneity, the power to detect inconsistency was low and this result cannot be 
interpreted as conclusive evidence of the consistency of the network. Results from four 
studies, including Ma Lin (21), were extreme in comparison with other studies, but these data 
points fitted poorly in both the NMA and the inconsistency model, indicating extreme 
heterogeneity rather than non-transitivity. 
 
Publication bias 
In pairwise meta-analysis there was no evidence for the exaggeration of treatment effects in 
smaller studies (a proxy for publication bias) in any of the comparisons (minimum p-
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value=0.300, Harbord test). In NMA the covariate effect for study SE indicated that estimated 
treatment effects tended to show a greater benefit in smaller, less precise studies, although 
this result was not significant (ROR per 0.2 change in SE: 0.83, 95% CrI 0.66-1.04) (Data 
Supplement 13). 
 
Discussion 
We present the results of an updated review and meta-analysis investigating the efficacy and 
toxicity of treatment regimens for LTBI (7). This review confirms that all currently 
recommended regimens (4) are safe and efficacious and provides more robust evidence to 
demonstrate the efficacy of rifamycin-containing regimens, including the three to four 
months RMP monotherapy, to prevent TB disease. Whilst we also included a new study on 
the efficacy for ETH-INH combination therapy, both INH and INH-ETH combination had 
zero TB cases in this small study, and the study therefore did not significantly add to the 
evidence of the network. There were no significant differences in treatment efficacy for the 
different regimens in HIV positive and HIV negative subjects, although there was a possible 
general weakening of efficacy in HIV positive populations. Studies in HIV positive 
populations have only been conducted relatively recently and are therefore highly correlated 
with year of publication; more recent studies were also associated with a modest decrease in 
treatment efficacy, so there may be some confounding. 
 
Aside from the efficacy of a particular regimen and its toxicity and risk of adverse events, in 
clinical practice three other key factors should be considered when making recommendations. 
These are the cost of a regimen, the length of time for which patients are taking treatment and 
pill burden. A recent systematic review showed that shorter regimens were associated with 
higher treatment completion rates (23). The relatively brief three-month RPT-based regimen 
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has obvious advantages in terms of shortened treatment length, with only 12 doses. 
Publications from a general population setting (15), amongst HIV infected persons (13), or 
children and adolescents (24) have demonstrated good efficacy and safety. Unfortunately, as 
these publications derive from the same core study, the evidence as demonstrated within our 
network remains limited. 
 
Only few other systematic reviews on the topic have been published recently. Our search 
revealed two papers, where LTBI treatment efficacy and toxicity has been part of a wider 
review (25,26) and a further three which focussed on specific populations, two on children 
(27,28) and one on HIV-infected adults (29). The nature of these reviews means that their 
study collection tends to be more restricted than ours, but the results are compatible with ours 
in all studies. 
 
Our search also revealed two ongoing registered trials. One of these (NCT02651259), which 
aims to evaluate the pharmacokinetics, acceptability and safety of the rifapentine-isoniazid 
regimen in pregnant and post-partum women is currently recruiting participants and is 
expected to complete recruitment in December 2018 (30). The other (NCT02980016) is a 
pragmatic trial which looks at incidence and treatment completion rates among an HIV 
positive population, comparing a single rifapentine-isoniazid course with a six month 
isoniazid regimen and in a second stage with a periodic rifapentine-isoniazid regimen (31). 
This trial is also in recruitment phase, scheduled to complete in June 2019. Both trials look at 
important aspects of rifapentine-based regimens and support the much-needed development 
of shorter and less frequent LTBI treatment regimens. 
 
Our study presents two parallel forms of meta-analysis. Effect estimates can sometimes show 
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greater benefit in pairwise comparisons compared to NMA, with the latter constraining 
treatment effects to be consistent across comparisons. Although not significantly different, it 
is possible that treatment effects reported in our pairwise results could be slightly 
overestimated.  
 
The main limitation of our work is the underlying studies, many of which have a high risk of 
bias and are small or use non-standard endpoint definitions. A number of publications 
reported on overlapping RCT populations; we carefully avoided double counting by applying 
standard inclusion rules to these studies. In general this meant including the study with the 
largest cohort and greatest follow up time, which was often the most recent work. Since the 
highest LTBI reactivation risk usually occurs shortly after infection, prolonging cohort 
follow-up time may lead to decreased effect estimates, particularly for long-term regimens. 
Our replacement of efficacy estimates from Samandari (2011)(14) with those from their 2015 
paper demonstrated this; the efficacy of 36 months INH treatment waned over time. It is 
possible, therefore, that our analysis provides conservative efficacy estimates in some 
instances particularly for longer regimens – in particular in high TB burden settings where 
there is much greater potential for reinfection. We tested for publication bias, however, our 
ability to do so was limited for some comparisons, due to sparse data. Lastly, whilst we 
provide stratified analyses for a number of co-variates, including HIV co-infection, there is a 
dearth of evidence on how concomitantly administered treatments such as HIV anti-
retrovirals (ART) may interact with LTBI treatment efficacy. Although there have been some 
recent insights (32), demonstrating an LTBI treatment-independent effect of early ART start 
on TB incidence (16), data points were too limited to include ART as a co-factor in our 
analysis.  
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In conclusion, despite limitations in underlying evidence including study quality and varying 
reporting standards, the evidence for safety and efficacy of most standard treatment regimens 
is robust, although there remains sparse evidence for the 9 month INH regimen. The evidence 
for rifamycin containing regimens including RPT is improving. More evidence is needed, 
particularly for RPT-based regimens and the INH-RMP combination, alternative treatments 
with shorter duration and lower pill burden, and to assess the impact of co-variates such as 
ART. It is reassuring nonetheless to reaffirm the strengthening evidence for shorter rifamycin 
regimens.  
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Figure 1:  Treatment network for a) all studies, b) those with active tuberculosis data 
and c) those with hepatotoxicity data*  
 
  
 
* Unlabelled connections indicate one study reporting that treatment pair; for two or more studies lines are proportionally 
thicker, and labelled with the number of studies. Colour coding indicates classes of treatment. Dotted boxes indicate a lack 
of data. RFB-INH: 300mg RFB plus 750mg INH twice weekly for 3 months, RFB-INH high: 600mg RFB plus 750mg INH 
twice weekly for 3 months. 4m- four months, etc., EMB- ethambutol; NH- isoniazid; PZA- pyrazinamide; RFB- rifabutin; 
RMP- rifampicin; RPT- rifapentine; TB- tuberculosis 
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Table 1: Odds ratios for the prevention of active tuberculosis and treatment rankings, 
derived from the network meta-analysis* 
Regimen OR vs. placebo (95% CrI) OR vs.  no treatment (95% CrI) Rank (95% CrI) 
No treatment 1.62 (1.06, 2.47) 1 (ref) 16 (14-16) 
Placebo 1 (ref) 0.62 (0.41, 0.94) 13 (11-15) 
INH 3-4m 0.93 (0.55, 1.50) 0.57 (0.31, 1.02) 13 (8-15) 
INH 6m 0.65 (0.50, 0.83) 0.40 (0.26, 0.60) 10 (7-12) 
INH 9m 0.75 (0.35, 1.62) 0.46 (0.22, 0.95) 11 (4-15) 
INH 12m 0.50 (0.41, 0.62) 0.31 (0.21, 0.47) 6 (4-10) 
RFB-INH 0.30 (0.05, 1.50) 0.18 (0.03, 0.95) 3 (1-15) 
RFB-INH (high) 0.30 (0.05, 1.52) 0.19 (0.03, 0.98) 3 (1-15) 
RPT-INH 0.58 (0.30, 1.12) 0.36 (0.18, 0.73) 8 (3-14) 
RMP 0.41 (0.19, 0.85) 0.25 (0.11, 0.57) 5 (1-12) 
RMP-INH 1m 1.05 (0.37, 2.77) 0.65 (0.23, 1.71) 14 (4-16) 
RMP-INH 3-4m 0.53 (0.36, 0.78) 0.33 (0.20, 0.54) 7 (4-11) 
RMP-INH-PZA 0.35 (0.19, 0.61) 0.21 (0.11, 0.41) 3 (1-8) 
RMP-PZA 0.53 (0.33, 0.84) 0.33 (0.18, 0.58) 7 (3-12) 
INH-EMB 0.87 (0.32, 2.36) 0.54 (0.19, 1.56) 12 (4-16) 
INH-EMB 12m 0.20 (0.04, 0.82) 0.12 (0.02, 0.54) 2 (1-11) 
 
* Comparisons versus placebo and no treatment. CrI- credible interval, EMB- ethambutol, INH- isoniazid, m- months, OR- 
odds ratio, PZA- pyrazinamide, RFB- rifabutin, RMP- rifampicin, RPT- rifapentine
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Figure 2: Comparison of odds ratios for active tuberculosis obtained from random 
effects pairwise meta-analysis with corresponding estimate from mixed treatment 
comparison (NMA)† 
 
 
vs. INH-EMB
vs. RMP-INH 3m
vs. RMP-PZA
vs. RPT-INH
vs. INH 12m
vs. INH 6m
vs. RMP-INH 1m
vs. RMP-INH 3m
vs. RMP-INH-PZA
vs. INH 12m
vs. RFB-INH
vs. RFB-INH (high)
vs. RMP
vs. RMP-INH 3m
vs. RMP-INH-PZA
vs. RMP-PZA
vs. RPT-INH
vs. RMP-INH 3m
vs. RPT-INH
vs. INH 12m
vs. INH 4m
vs. INH 6m
vs. INH 9m
vs. RMP-INH 1m
vs. RMP-INH 3m
vs. RMP-INH-PZA
vs. RMP-PZA
vs. INH 12m
vs. INH 4m
vs. INH 6m
vs. INH-EMB 12m
vs. RMP
vs. RMP-INH 3m
vs. RMP-INH-PZA
vs. RMP-PZA
vs. RMP-INH 3m
vs. RMP-PZA
vs. RMP-INH 3m
vs. RMP-INH-PZA
vs. RMP-INH-PZA
vs. RMP-PZA
vs. RMP-INH 3m
vs. RMP-PZA
INH 12m
INH 4m
INH 6m
INH 9m
No treatment
Placebo
RMP
RMP-INH 1m
RMP-INH 3m
RPT-INH
.02 .05 .1 .2 .5 1 2 5 10 20 50
Direct MTC
20 
 
† Where data on direct comparisons of treatment pairs are available for active tuberculosis these may be pooled via standard 
meta-analysis for each pair of treatments in turn. The resulting estimates are then compared with those obtained from the 
NMA analysis, which incorporates indirect evidence and the overall network structure in addition to the direct evidence. 
EMB- ethambutol, INH- isoniazid, m- months, PZA- pyrazinamide, RFB- rifabutin, RMP- rifampicin, RPT- rifapentine 
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Table 2. Odds Ratio for Hepatotoxicity, derived from the Network Meta-analysis 
Regimen 
OR vs. no treatment 
(95% CrI) 
OR vs. placebo 
(95% CrI) 
Rank (95% 
CrI) 
No treatment 1.00 (1.00, 1.00) 0.24 (0.06, 0.75) 4 (2-7) 
Placebo 4.12 (1.33, 15.88) 1.00 (1.00, 1.00) 9 (7-10) 
INH 6m 1.10 (0.40, 3.17) 0.27 (0.10, 0.60) 5 (3-7) 
INH 9m 1.70 (0.35, 8.05) 0.41 (0.08, 1.62) 6 (3-10) 
INH 12m 2.72 (0.96, 7.44) 0.66 (0.26, 1.32) 8 (6-10) 
RPT-INH 0.52 (0.13, 2.15) 0.13 (0.03, 0.42) 2 (1-5) 
RMP 0.14 (0.02, 0.81) 0.03 (<0.02, 0.16) 1 (1-2) 
RMP-INH 3-4m 0.72 (0.21, 2.37) 0.17 (0.05, 0.46) 3 (2-6) 
RMP-INH-PZA 2.41 (0.25, 20.02) 0.58 (0.07, 3.72) 7 (2-10) 
RMP-PZA 3.32 (0.99, 11.23) 0.80 (0.25, 2.17) 9 (6-10) 
 
CrI- credible interval; INH- isoniazid; PZA- pyrazinamide; RMP- rifampicin; RPT- rifapentine 
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